1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 19, 1996
CONCENTRA CORPORATION
------------------------------------------------------
(Exact name of Registrant as specified in its Charter)
DELAWARE 0-25498 04-2827026
- --------------- ------------ -------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
21 NORTH AVENUE, BURLINGTON, MASSACHUSETTS 01803-3301
-----------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(617) 229-4600
----------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS
On November 19, 1996, the Company announced the appointment of Alex
Braverman as the Company's new Vice President and Chief Financial Officer. Mr.
Braverman has been employed by the Company since 1994 and has most recently
served as the Company's Corporate Controller. Mr. Braverman replaces Gerald M.
Schimmoeller, who resigned his position as Vice President and Chief Financial
Officer effective as of November 22, 1996 to assume the position of Vice
President and Chief Financial Officer at AlphaGene, Inc., a biotechnology
company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CONCENTRA CORPORATION
By: /s/ Alex Braverman
-------------------------------
Alex Braverman, Vice President
and Chief Financial Officer
Date: November 21, 1996